The Clinical Pharmacology of Anastrozole

@article{Bao2011TheCP,
  title={The Clinical Pharmacology of Anastrozole},
  author={Ting Bao and Michelle A. Rudek},
  journal={European Oncology and Haematology},
  year={2011},
  volume={07},
  pages={106}
}
  • T. BaoM. Rudek
  • Published 2011
  • Medicine
  • European Oncology and Haematology
View via Publisher
touchoncology.com
16 Citations
Background Citations
3
Methods Citations
1

16 Citations

Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside

The structure, biological function, and underlying mechanisms of AMPs are presented and the recent experimental studies and clinical trials on anticancer peptides in different cancer types as well as the challenges of their clinical application are discussed.

Anticancer Potential of Moringa oleifera on BRCA-1 Gene: Systems Biology

It is proposed that bioactive compounds from M oleifera may be potential novel drug candidates in the treatment of breast cancer.

Anti-cancer Potential of Moringa oleifera on BRCA1 Gene: Systems Biology

It is proposed that bioactive compounds from M. oleifera may be potential hit drug candidates against breast cancer, and these compounds could serve as anti-cancer agents.

Anastrozol jako inhibitor aromatazy – nowe podejścia w terapii raka piersi u kobiet w wieku pomenopauzalnym

Wstep. Anastrozol jest chemoterapeutykiem stosowanym w leczeniu nowotworow piersi u kobiet po menopauzie. Warunkiem powodzenia tego typu leczenia jest obecnośc receptorow estrogenowych w komorkach…

Cytotoxic effect of transdermal invasomal anastrozole gel on MCF-7 breast cancer cell line

It was concluded that the developed anastrozole invasomes enhanced the transdermal flux and the results obtained encouraged the use of the anastroscopic invasomal gel for the potential treatment of breast cancer in post-menopausal women.

Anastrozole as aromatase inhibitor – new approaches to breast cancer treatment in postmenopausal women

Biodegradable nano-tools that deliver anastrozole to the target site with an increase in its half-life to 144 hours are a promising method and can be achieved by using a transdermal anast rozole administration system, which is a completely non-invasive method of treatment.

EFFECTS OF ANASTROZOLE ADMINISTRATION ON SERUM ESTROGEN LEVEL OF FEMALE RABBIT

Assessment of the effects of anastrozole use as hormonal treatment of breast cancer on the serum estrogen level in an animal model found the decrease is significant statistically and the comparison of the serumosterone levels of both the experimental groups B and C was found to be statistically insignificant.

Evaluation and optimization of pH-responsive niosomes as a carrier for efficient treatment of breast cancer

The optimum formula showed localized TXC in a tumour and consequently a significant anti-tumour efficacy compared with free TXC, and could be a promising formula for the efficient treatment of breast cancer.

FUNGAL KAYNAKLI BASSİATİN’İN (3R,6R) MEME KANSERİ HÜCRE HATLARI ÜZERİNDEKİ ETKİSİNİN ARAŞTIRILMASI

Bu tez calismasi; TUBITAK tarafindan 215S096 numarali proje ve Hacettepe Universitesi Bilimsel Arastirmalar Birimi tarafindan FHD-2017-13202 numarali proje ile desteklenmistir.

Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells

Anastrozole showed cytotoxic effects against the MCF7, HepG2, and PC3 cell lines as determined in-vitro by the MTT assay and its mechanism of apoptosis in living cells was determined by high content screening (HCS).

References

SHOWING 1-10 OF 32 REFERENCES

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.

A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

The efficacy and tolerability of anastrozole and megestrol acetate were compared in 386 postmenopausal women with advanced breast carcinoma who progressed after tamoxifen therapy.

POTENCY AND SELECTIVITY OF THE NON‐STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS

It is concluded that CGS 16949A is a potent oestrogen suppressant in postmenopausal patients but that its effect is not totally selective.

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study.

It can be concluded that ACE and ANG II activity independently modulate aromatase activity and this suggests a new physiological role for ACE and Angiotensin II.

In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A

The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers.

Overall, there was no evidence to suggest that anastrozole has any clinically relevant effects on the pharmacokinetic and pharmacodynamic effects of warfarin.

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

Switching to anastrozole after the first 2 to 3 years of treatment is well tolerated and significantly improves event-free and recurrence-free survival in postmenopausal patients with early breast cancer.

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?